Toyota suspended U.S. sales of some of its most popular vehicles — including the best-selling car in America, the Camry — to fix sticking gas pedals that could make the cars accelerate without warning.
In another blow to the world’s No. 1 automaker, Toyota Motor Corp. said Tuesday it would halt some production at six assembly plants beginning the week of Feb. 1 "to assess and coordinate activities."
The company said it would stop selling eight models of cars and trucks, a significant portion of its fleet. The suspension comes after a recall of the same models last week involving 2.3 million vehicles.
Toyota has said it was unaware of any accidents or injuries due to the pedal problems associated with the recall, but could not rule them out for sure.
"This action is necessary until a remedy is finalized," said Bob Carter, Toyota’s group vice president and general manager.
The Japanese automaker said the sales suspension includes the following models: the 2009-2010 RAV4, the 2009-2010 Corolla, the 2007-2010 Camry, the 2009-2010 Matrix, the 2005-2010 Avalon, the 2010 Highlander, the 2007-2010 Tundra and the 2008-2010 Sequoia.
Some dealers suggested taking vehicles to dealerships for inspections if people have safety concerns.
Aaron Bragman, an auto analyst for the consulting firm IHS Global Insight in Troy, Mich., said Toyota typically sells about 65,000 Camrys and Corollas a month, and the frozen sales could strike at the company’s bottom line and reputation for quality.
"That’s huge if they can’t sell these and they don’t have a fix identified. They need to go and get a solution to this fast," Bragman said.
Toyota sold more than 34,000 Camrys in December, making the midsize sedan America’s best-selling car. It commands 3.4 percent of the U.S. market and sales rose 38 percent from a year earlier. Sales of the Corolla and Matrix, a small sedan and a hatchback, totaled 34,220 last month, making up 3.3 percent of the market and sales up nearly 55 percent from December of 2008.
Toyota spokesman Mike Michels said production would be suspended on the affected vehicle lines this week and it was unclear exactly when it would resume. In…
Reports of sudden acceleration in Toyota vehicles has led Ken Bensinger and Ralph Vartabedian to investigate the claims that certain dates and models of Toyotas are designed defectively. They concluded that the original explanation, floor mats getting stuck under the accelerator pedal, is not likely the key problem. Instead, they suggest that the electronic throttles in models after 2002 are malfunctioning, in some cases, leading to terrifying and deadly accidents.
That’s bad. But not even the only problem Toyota is facing. Mr. Bensinger and Mr. Vartabedian have also written about a federal investigation into Corolla and Matrix cars, model year 2006, which are subjects of complaints about stalling, sometimes while being driven at freeway speeds, and sometimes in dangerous spots, such as in the middle of intersections.
The TIME article cited below also points out that even though Toyota is recalling millions of vehicles at risk for speeding out of control, it is not clear the auto manufacturer understands what the problem is – the floor mat being stuck under the accelerator pedal, or a problem with the electronic engine control system malfunctioning, or a combination of these problems as well as others? Toyota’s critics are complaining that the problem is with the electronic engine control system, though this allegation has yet to be proven.
Keep reading for more details and a new Toyota tune at the end.
Eric Weiss was stopped at a busy Long Beach intersection last month when he said his 2008 Toyota Tacoma pickup unexpectedly started accelerating, forcing him to stand on the brakes to keep the bucking truck from plowing into oncoming cars.
Toyota Motor Corp. says the gas pedal design in Weiss’ truck and more than 4 million other Toyota and Lexus vehicles makes them vulnerable to being trapped open by floor mats, and on Wednesday, it announced a costly recall to fix the problem.
But Weiss is convinced his incident wasn’t caused by a floor mat. He said he removed the mats in his truck months earlier on the advice of his Toyota dealer after his truck suddenly accelerated and rear-ended a BMW.
"The brakes squealed and the engine roared," the 52-year-old cabinet maker said
The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday September 29, 2016:
Qualcomm Said to be in Talks to Acquire NXP Semiconductors for $30B+
Qualcomm Inc. (NASDAQ: QCOM) is said in talks to acquire NXP Semiconductors NV (NASDAQ: NXPI), according to sources as reported by Dow Jones on Thursday. The sources said a deal, which could happen over the next two to three months, would likely be valued at over $30 billion, though NXP's market cap was already over $32 billion following the report.
By insidesources. Originally published at ValueWalk.
IRS Walks Tightrope in Plan to Use Private Debt Collectors
The Internal Revenue Service is looking to use private contractors to help collect tax debt but some warn there is a risk of increased scams and abuse.
The IRS announced its intent to use private debt collectors Sept. 26 in response to a congressional order. The federal agency hopes to have the program operational by spring. The idea could help the agency to more efficiently collect tax debt, but it might also be opening the door to fraud and abuse.
“What makes it worse is the prevalence of these scam artists who call pretending to be IRS collectors,ȁ...
The BEA changed the name from “final estimate” to “third estimate” because GDP is subject to revisions years or even decades later.
I am curious how this would impact the Atlanta Fed GDPNow forecast and the FRBNY Nowcast estimate both due out tomorrow. I have a detailed answer from Pat Higgins at the Atlanta Fed, creator of GDPNow.
I can give you a more detailed answer tomorrow after the GDPNow update is released. We don’t do an update today beca...
U.S. stocks fell as banks retreated amid growing concern that Deutsche Bank AG’s woes will spread to the global financial sector. Health-care shares sank on speculation tighter regulations will crimp profits.
In early 2009, the seven largest publicly traded college operators were worth a combined $51 billion. Today, they’ve been all but wiped out.
When Barack Obama took office, America’s seven largest publicly traded college operators were worth a combined $51 billion, with more than 815,000 students enrolled at campuses spread across the country. The schools were flooded with with people seeking shelter from the recession, returning to school to pick up new skills.
Almost eight years later, the industry has been decimated. The seven largest listed operators are worth just over $6 billion, and the most valuable co...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
I was so pleased yesterday by the announcement that I have joined the Research team at GoldCore as it meant that I could finally start talking about it and was back in a role that lets me indulge in my passion by researching and geeking out on all things gold, silver and money.
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer. One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."
Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.
Genetic components are the DNA sequences that are 'inherited.' Some of these genes are stronger than others in their expression (e.g., eye color). Yet, some genes turn on or off due to external factors (environmental), and it is und...
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW)
nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Site owned and operated by PSW Investments, LLC. Contact us at: 403 Central Avenue, Hawthorne, NJ 07506. Phone: (201) 743-8009. Email: email@example.com.